2篇
您的检索式：作者名="Dick C Chan"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Origin and therapy for hypertriglyceridaemia in type 2 diabetes显示文摘Hypertriglyceridaemia(HTG) is a risk factor for cardiovascular disease(CVD) in type 2 diabetes and is caused by the interaction of genes and non-genetic factors, specifically poor glycaemic control and obesity. In spite of statin treatment, residual risk of CVD remains high in type 2 diabetes, and this may relate to HTG and atherogenic dyslipidemia. Treatment of HTG emphasises correcting secondary factors and adverse lifestyles, in particular, diet and exercise. Pharmacotherapy is also required in most type 2 diabetic patients. Statins are the first-line therapy to achieve recommended therapeutic targets of plasma low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. Fibrates, ezetimibe and n-3 fatty acids are adjunctive treatment options for residual and persistent HTG. Evidence for the use of niacin has been challenged by non-significant CVD outcomes in two recent large clinical trials. Further investigation is required to clarify the use of incretin-based therapies for HTG in type 2 diabetes. Extreme HTG, with risk of pancreatitis, may require insulin infusion therapy or apheresis.New therapies targeting HTG in diabetes need to be tested in clinical endpoint trials. The purpose of this review is to examine the current evidence and provide practical guidance on the management of HTG in type 2 diabetes. | Jing Pang Dick C Chan Gerald F Watts | 2014 | World Journal of Diabetes2014，5，2： | 2 |
| 2 | Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet显示文摘 | Chan Dick C Watts Gerald F Gan Seng Khee Ooi Esther M M Barrett P Hugh R | 2010 | Diabetes Care2010，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员